NS-229 is an investigational selective Janus kinase 1 (JAK1) inhibitor designed to prevent tissue damage caused by EGPA by suppressing immune cell activation. A global, randomized, double-blind ...

Janus kinase (JAK) inhibitors represent another innovative class of medications that block pathways involved in the inflammatory process. These oral medications offer alternatives for patients who ...

The strategy is large with over $7 billion in assets. Many holdings overlap with those in small-growth sibling Janus Henderson Venture, which has over $3 billion in assets, and mid-growth Janus ...

Schommer has worked alongside Rao for much of his career, starting in 2007 as an analyst at Marsico Capital Management before moving to Janus in 2013, and then becoming comanager on this strategy ...

The Fund seeks capital appreciation. The Fund pursues its investment objective by investing at least 50% of its equity assets in small-sized companies, which are defined by portfolio management as ...

Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound suitable for clinical testing — a drug candidate. It is based on ...

Mar. 25, 2025 — A drug typically prescribed for arthritis halts brain-damaging seizures in mice that have a condition like epilepsy, according to researchers. If the drug proves viable for human ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

The Fund aims to provide a return of at least the Solactive United Kingdom All Cap Index (incl. Investment Trusts) (the reference index) +0.5% per annum, before the deduction of charges, over any 5 ...